Dalbavancin

Lipoglycopeptide Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Dalbavancin is a drug in the Lipoglycopeptide Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 2014. Recorded indications include Bacterial infection of skin, Infection of skin AND/OR subcutaneous tissue and Staphylococcal infection of skin.

• Drug class: Lipoglycopeptide Antibacterial.
• Indications: Bacterial infection of skin, Infection of skin AND/OR subcutaneous tissue and Staphylococcal infection of skin.
• ATC code: J01XA04 (Glycopeptide antibacterials).
• Molecular formula: C88H100Cl2N10O28; molecular weight 1816.71 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Bacterial infection of skin
• Infection of skin AND/OR subcutaneous tissue
• Staphylococcal infection of skin

Mechanism & targets

• Established pharmacologic class: Lipoglycopeptide Antibacterial

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2014-12-18	EMA	—	—
2014-05-23	FDA	—	DURATA THERAPS INTL

ATC classification

ATC code	Therapeutic hierarchy
J01XA04	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER ANTIBACTERIALS › Glycopeptide antibacterials

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Off label use	179.4
Product preparation error	72.1
Infusion site extravasation	67.0
Rash	56.0
Erythema	53.2
Back pain	52.0
Pruritus	48.4

Chemical structure

• Molecular formula: C₈₈H₁₀₀Cl₂N₁₀O₂₈
• Molecular weight: 1816.71 g/mol
• CAS number: 171500-79-1
• InChIKey: KGPGQDLTDHGEGT-SZUNQUCBSA-N
• PubChem CID: 16134627

CN[C@@H]1C2=CC(OC3=CC([C@@H]4NC(=O)[C@@H](CC5=CC=C(OC6=C(O[C@@H]7O[C@@H]([C@@H](O)[C@H](O)[C@H]7NC(=O)CCCCCCCCC(C)C)C(O)=O)C7=CC(=C6)[C@@H](NC4=O)C(=O)N[C@@H]4C6=CC(=C(O)C=C6)C6=C(O[C@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]8O)C=C(O)C=C6[C@H](NC(=O)[C@@H](NC4=O)[C@H](O)C4=CC(Cl)=C(O7)C=C4)C(=O)NCCCN(C)C)C=C5)NC1=O)=C(Cl)C(O)=C3)=C(O)C=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dalbavancin used for?

DrugCentral lists the following indications for Dalbavancin: Bacterial infection of skin, Infection of skin AND/OR subcutaneous tissue and Staphylococcal infection of skin.

When was Dalbavancin first approved?

Dalbavancin was first approved by the FDA in 2014.

What drug class does Dalbavancin belong to?

Dalbavancin is in the Lipoglycopeptide Antibacterial class.

What is the chemical formula of Dalbavancin?

Dalbavancin has the molecular formula C88H100Cl2N10O28 and a molecular weight of 1816.71 g/mol.

Sources

• DrugCentral drug card 777 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3301650 — compound record and bioactivity
• PubChem CID 16134627 — chemical identifiers
• DrugBank DB06219 — drug record
• FDA UNII 808UI9MS5K — substance identity
• DailyMed: FDA labels for Dalbavancin — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.